Medical Devices Australia

Australia Point-of-Care Molecular Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Point-of-Care Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $48.4 Mn Placeholder estimate
Estimate 2025 $54.0 Mn 1.4% of the global market
Projected 2034 $146.2 Mn 170.7% Adds $92.2 Mn over 9 forecast years
CAGR 2025–2034 11.7% Faster than 65% of 193 Medical Devices markets here
Key players 5
  • Australia is 1.4% of the global market.
  • In APAC, the largest is China at $320.3 Mn.
  • Fastest growing: India at 12.8% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$92.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Point-of-Care Molecular Diagnostics Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $48.4 Mn — —
2025 (base) $54.0 Mn +$5.7 Mn —
2026 (forecast) $60.3 Mn +$6.3 Mn +11.7%
2027 (forecast) $67.4 Mn +$7.1 Mn +24.8%
2028 (forecast) $75.3 Mn +$7.9 Mn +39.4%
2029 (forecast) $84.1 Mn +$8.8 Mn +55.7%
2030 (forecast) $93.9 Mn +$9.8 Mn +73.9%
2031 (forecast) $104.9 Mn +$11.0 Mn +94.2%
2032 (forecast) $117.2 Mn +$12.3 Mn +117%
2033 (forecast) $130.9 Mn +$13.7 Mn +142.3%
2034 (forecast) $146.2 Mn +$15.3 Mn +170.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Point-of-Care Molecular Diagnostics Market Analysis at a glance
Market size, 2025$54.0 Mn placeholder estimate
Forecast, 2034$146.2 Mn placeholder estimate
Growth (CAGR), 2025–203411.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, technology and end user (see all)
Key playersCepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA, Visby Medical (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Point-of-Care Molecular Diagnostics Market Analysis Executive Summary

Point-of-care molecular diagnostics run PCR and similar DNA tests near the patient, giving lab-quality results in minutes.

Key segments of the point-of-Care Molecular Diagnostics market include test (Respiratory Infections, Sexually Transmitted Infections and Hospital Infections) and technology (PCR and Isothermal Amplification).

Bar chart: Australia Point-of-Care Molecular Diagnostics market size, 2024–2034, placeholder estimates. $48.4 Mn in 2024, $54.0 Mn in 2025 and $146.2 Mn in 2034, 11.7% CAGR.
Australia Point-of-Care Molecular Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Point-of-Care Molecular Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the point-of-Care Molecular Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the point-of-Care Molecular Diagnostics market.

Competitive Landscape for Point-of-Care Molecular Diagnostics Market in Australia

The point-of-Care Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Point-of-Care Molecular Diagnostics Market in Australia

Point-of-Care Molecular Diagnostics in Australia: rules and payment

Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how point-of-Care Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Point-of-Care Molecular Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Point-of-Care Molecular Diagnostics in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 4th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Point-of-Care Molecular Diagnostics market in Australia?
Placeholder estimate: about $54.0 Mn in 2025, rising to about $146.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Point-of-Care Molecular Diagnostics market in Australia growing?
Placeholder estimate: about 11.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Point-of-Care Molecular Diagnostics market report cover?
The report splits the market by test (Respiratory Infections, Sexually Transmitted Infections, Hospital Infections, Oncology), technology (PCR, Isothermal Amplification) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Point-of-Care Molecular Diagnostics market?
Key players include Cepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA and Visby Medical.
What is driving the Point-of-Care Molecular Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.
Who regulates Point-of-Care Molecular Diagnostics in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How much research is published on Point-of-Care Molecular Diagnostics?
PubMed lists 43 papers on Point-of-Care Molecular Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Australia

See all

Related on diagnostics and lab testing

See the topic